Novartis AG
Swiss ExchangeTotal Valuation
Novartis AG carries a market capitalization of 238.70B, placing it among publicly traded companies globally. Its enterprise value stands at 331.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 238.70B |
| Enterprise Value | 331.30B |
Share Statistics
Novartis AG currently has 1.91B shares outstanding.
| Shares Outstanding | 1.91B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Novartis AG trades at a trailing price-to-earnings ratio of 21.49. The price-to-sales ratio is 5.14, and the price-to-book ratio stands at 7.66.
| PE Ratio | 21.49 |
| PS Ratio | 5.14 |
| PB Ratio | 7.66 |
| P/TBV Ratio | -10.35 |
| P/FCF Ratio | 13.07 |
| P/OCF Ratio | 15.17 |
Enterprise Valuation
On an enterprise value basis, Novartis AG trades at an EV/EBITDA multiple of 14.65 and an EV/FCF ratio of 14.14. The EV/Sales ratio of 5.86 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 19.24 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.86 |
| EV / EBITDA | 14.65 |
| EV / EBIT | 19.24 |
| EV / FCF | 14.14 |
Financial Position
Novartis AG maintains a current ratio of 0.85, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 120.73, indicating elevated leverage, while an interest coverage ratio of 18.58 demonstrates strong ability to service its debt obligations.
| Current Ratio | 0.85 |
| Quick Ratio | 0.53 |
| Debt / Equity | 120.73 |
| Debt / EBITDA | 2.08 |
| Interest Coverage | 18.58 |
Financial Efficiency
Novartis AG posts a return on equity of 34.44 and a return on invested capital of 18.42.
| Return on Equity (ROE) | 34.44 |
| Return on Assets (ROA) | 12.39 |
| Return on Invested Capital (ROIC) | 18.42 |
| Return on Capital Employed (ROCE) | 18.55 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.30 |
Taxes
Over the trailing twelve months, Novartis AG has paid 2.27B in income taxes, reflecting an effective tax rate of 14.38.
| Income Tax | 2.27B |
| Effective Tax Rate | 14.38 |
Stock Price Statistics
Novartis AG's stock has gained approximately 28.1631% over the past 52 weeks. The 50-day moving average sits at 118.69, while the 200-day moving average is 114.37.
| Beta (5Y) | N/A |
| 52-Week Price Change | 28.1631% |
| 50-Day Moving Average | 118.69 |
| 200-Day Moving Average | 114.37 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Novartis AG generated 56.58B in revenue and converted that into 13.53B in net income, yielding earnings per share of 6.98. EBITDA reached 22.62B, while operating income came in at 17.22B.
| Revenue | 56.58B |
| Gross Profit | 42.65B |
| Operating Income | 17.22B |
| Pretax Income | 15.78B |
| Net Income | 13.53B |
| EBITDA | 22.62B |
| EBIT | 17.22B |
| Earnings Per Share (EPS) | 6.98 |
Balance Sheet
Novartis AG holds 6.98B in cash and equivalents against 47.00B in total debt, resulting in a net debt position of 38.19B. Total book value stands at 37.99B, with working capital of -4.77B providing operational flexibility.
| Cash & Cash Equivalents | 6.98B |
| Total Debt | 47.00B |
| Net Debt | 38.19B |
| Equity (Book Value) | 37.99B |
| Book Value Per Share | 19.75 |
| Working Capital | -4.77B |
Cash Flow
Novartis AG produced 19.18B in operating cash flow over the past twelve months. After subtracting -3.21B in capital expenditures, free cash flow totaled 15.96B - equivalent to 8.30 per share.
| Operating Cash Flow | 19.18B |
| Capital Expenditures | -3.21B |
| Free Cash Flow | 15.96B |
| FCF Per Share | 8.30 |
Margins
Novartis AG operates with a gross margin of 75.38, reflecting its pricing power and cost economics. The operating margin of 30.43 and net profit margin of 23.92 provide insight into operational efficiency.
| Gross Margin | 75.38 |
| Operating Margin | 30.43 |
| Pretax Margin | 27.90 |
| Profit Margin | 23.92 |
| EBITDA Margin | 39.97 |
Dividends & Yields
The company's payout ratio of 64.34 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 4.51 |
| Dividend Yield | N/A |
| Payout Ratio | 64.34 |
| Shareholder Yield | 0.94 |
| FCF Yield | 7.65 |
Stock Splits
Novartis AG's most recent stock split took place on October 4, 2023 with a 5:6 split ratio.
| Last Split Date | 10/4/2023 |
| Split Ratio | 5:6 |
Scores
Novartis AG posts an Altman Z-Score of 5.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.30 |